bluuebunny/crossref_metadata_2025_split huggingface dataset:
Acute mxyeloblastic leukemia two years after diagnosis of non‐Hodgkin lymphoma
Authors: Harris Richard E. , Seo In Sook , Provisor Deborah , Otter Marlene , Baehner Robert L. 
Published: February 2007

AbstractThe 18‐year‐old white male developed acute myeloblastic leukemia (AML) 25 months after diagnosis of poorly differentiated lymphocytic lymphoma, diffuse pattern (PDLL‐D), involving cervical, supraclavicular, and mediastinal lymph nodes as well as bone marrow. Treatment of the lymphoma consisted of 2,000 rads to the mantel area and 18 months of chemotherapy with intravenous (IV) methotrexate (400 mg/m2), vincristine, and prednisone, alternating every two weeks with IV cyclophosphamide (1,000 mg/m2), vincristine, and prednisone plus monthly intrathecal methotrexate. Thereafter, a complete remission was maintained without therapy until the onset of AML. Several pseudodiploid clones containing multiple structural rearrangements and a hypodiploid clones were identified in the circulating blood at the time of diagnosis of AML. Induction therapy consisting of cytosine arabinoside, 5‐aza‐cytidine, vincristine, and prednisone was unsuccessful, and the patient died of sepsis two months after diagnosis. This case calls attention to the increased risk for subsequent acute nonlymphocytic leukemia in patients previously treated for nonhodgkin lymphoma.
Malignant pheochromocytoma in childhood: Report of a case with familial neurofibromatosis
Authors: Quissel Barbara , Mohammad Akbar , Bauer John H. , Hakami Nasrollah 
Published: February 2007

AbstractA 14‐year‐old male with familial neurofibromatosis and widely disseminated malignant pheochromocytoma is described. Current criteria for the diagnosis and management of this rare malignancy are discussed.
Implementation of adjuvant therapy for breast cancer in the St. Louis metropolitan area: 1976–1977
Authors: Van Amburg Albert , Oppenheim Judith , Presant Cary A. , Oliver Joel 
Published: February 2007

AbstractIn order to determine the extent of implementation of adjuvant chemotherapy for stage II carcinoma of the breast in the St. Louis area, records of all patients with stage II carcinoma of the breast treated with standard or modified radical mastectomy in five different St. Louis hospitals were reviewed. Between July 1, 1976, and July 1, 1977 (17 months after publication of preliminary L‐PAM results and 4 months after publication of preliminary CMF results), 73% of 24 premenopausal patients and 55% of 58 postmenopausal patients received adjuvant chemotherapy. Ten percent of premenopausal and 31% of postmenopausal patients received therapy other than CMF or L‐PAM. Compared to premenopausal patients in university‐affiliated hospitals, premenopausal patients in community hospitals tended to receive radiation therapy more commonly and chemotherapy alone less often (P < 0.1). Compared to postmenopausal patients in university‐affiliated hospitals, postmenopausal patients in community hospitals more commonly received chemotherapy alone, and less often received no adjuvant therapy (P < 0.05). We conclude that results of adjuvant chemotherapy trials can be rapidly implemented into standard practice both in university‐affiliated and community hospitals. Since 12 of 52 patients receiving adjuvant chemotherapy in fact received non‐standard, unpublished regimens, improvements in phase IV drug development may be required to prevent potentially deleterious modifications of published recommendations.
Reduced antithrombin III levels during L‐asparaginase therapy
Authors: Buchanan George R. , Holtkamp Christine A. 
Published: February 2007

AbstractAntithrombin III levels were measured in serum before, during, and after therapy with three different dosage regimens of L‐asparaginase in 11 children with acute lymphoblastic leukemia. Levels determined by both functional and immunologic methods were transiently reduced during alternate‐day or daily L‐asparaginase treatment but not affected when the drug was administered only every 10 days. The probable mechanism of this effect is impaired hepatic synthesis of antithrombin III, resembling the acute and transient deficiency of other asparagine‐rich proteins during L‐asparaginase administration.
Adriamycin and splenectomy in the treatment of histiocytic medullary reticulosis
Authors: Pizzuto Javier , Aviles Agustin , Conte Guillermo , Morales Manuel , Ambriz Raul , Butron Luis 
Published: February 2007

AbstractHistiocytic medullary reticulosis (HMR) is a rare, malignant disorder with unsatisfactory response to various chemotherapeutic agents that have been used up to the present time.The purpose of this communication is to describe the first patient with this disease in whom an immediate, complete remission was obtained using only adriamycin. Four months after institution of this treatment, a staging laparotomy and splenectomy revealed residual disease in the spleen only. Adriamycin was continued as the sole agent, to the full calculated dose, followed by maintenance therapy consisting of cyclophosphamide. The patient continues to be in complete remission 35 months after diagnosis was established.
Cancer of the extrahepatic bile ducts
Authors: Bedikian A. Y. , Valdivieso M. , De La Cruz A. , Martin R. , Luna M. , Guinee V. F. , Bodey G. P. 
Published: February 2007

AbstractCase histories of 47 patients with histologically confirmed carcinoma of extra‐hepatic bile ducts presenting to M. D. Anderson Hospital and Tumor Institute over a 30‐year period were studied. The disease was more common in males during the sixth and seventh decades of life. A third of the patients had history of cholelithiasis. Four patients had prior history of chronic ulcerative colitis and one patient had congenital choledochal cyst prior to development of cancer of the bile duct. Jaundice was the earliest and the most common presenting sign. The tumor was located in the common bile duct more often than in the hepatic ducts. The overall median survival was eight months with two‐year and five‐year survival rates of 15% and 3%, respectively. The respective values for patients who had resectable tumors were 21.7 months, 57% and 20%. Ascending cholangitis was a frequent complication in patients treated with dilation and intubation and, overall, hepatic failure and systemic infection were more frequent causes of death than distant metastases.
A clinical trial of hyperalimentation in children with metastatic malignancies
Authors: Van Eys J. , Copeland E. M. , Cangir A. , Taylor G. , Teitell‐Cohen B. , Carter P. , Ortiz C. 
Published: February 2007

AbstractIn a controlled, randomized prospective clinical trial the utility of intravenous hyperalimentation (IVH) in the administration of and tolerance to chemotherapy was tested. The conclusions reached were 1) IVH is safe with a tolerable infection rate; 2) infectious complications correlate significantly with the nutritional status of the patient, with the presence of IVH being only a secondary factor; 3) IVH may be used to rehabilitate patients nutritionally, even those on intensive chemoterhapy; 4) the ability to deliver chemotherapy to patients seems to be improved by IVH, especially in malnourished patients in a late stage of disease.
Utility of density gradient centrifugation for fractionation of leukemic bone marrow
Authors: Bakkeren J. A. J. M. , De Vaan G. A. M. 
Published: February 2007

AbstractComparison of the distribution pattern of leukemic and normal bone marrow cells, obtained by density gradient centrifugation, may give information about the location of the blockade in the differentiation pathway from stem cell to mature leukocyte, as is supposed to exist in acute leukemia.As a control group 12 children with acute lymphoblastic leukemia (ALL), in complete remission and after cessation of all antileukemic therapy, were studied. By centrifugation over a discontinuous bovine serum albumin (BSA) density gradient, good reproducibility of the partition of the bone marrow cell population was obtained, with a peak in the more dense region. The cells capable of incorporation of [3H] thymidine in vitro were present predominantly in the lower density range.In 9 patients with lympho‐ or myeloproliferative malignancies (3 with o‐cell ALL, 2 with T‐cell malignant lymphoma, 1 with B‐cell malignant lymphoma, 3 with various malignancies of the myeloid‐monocytoid series) similar fractionation on the BSA gradient revealed a different cell partition pattern as compared with the control group. The peak of the distribution curve was located in the less dense region. Highest [3H] thymidine incorporation values were measured in vitro with cells from the lower density region.At last the importance of purely practical considerations in the choice of material for density gradient fractionation is stressed. Application of density gradient centrifugation methods could probably be helpful in attributing to cells from acute leukemia a place in the normal differentiation pathway.
Eosinophilic Granuloma of Bone
Authors: Slater James M. , Swarm Orval J. 
Published: February 2007

AbstractEosinophilic granuloma of bone is an uncommon granulomatous process for which therapy recommendations vary considerably. Consequently, a survey of the world literature from 1940 to 1974 was undertaken in an attempt to develop more concrete guidelines. This survey revealed that the disease manifests itself primarily in males under 20 years of age of all races. The most common symptom is pain, with or without swelling. Multiple sites in a single case are frequent. The clinical course is generally benign, unlike Letterer‐Siwe disease or Hand‐Schuller‐Christian disease. A remission rate of 95% was noted, with relapses usually occurring as distant disease within the first year. Simple excision or curettage was the most common surgical procedure utilized, and radiotherapy doses varied widely. Excellent local control of the disease can be provided using conservative surgery, low‐dose irradiation, or both. Morbidity secondary to pathologic fracture or to overly aggressive treatment are the major concerns, not failure to control the disease.
Aminoglutethimide in the management of metastatic breast cancer
Authors: Savaraj Niramol , Troner Michael B. 
Published: February 2007

AbstractAminoglutethimide (AG) with Dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptor. Objective tumor response (CR + PR) has been achieved in 13 of 26 patients. Responses were seen in soft tissue, bone, and pleura. Six of 26 patients had stable disease and seven of 26 patients had progressive disease. The median duration of response is 12.8 months. The median survival for the responders has not been reached. Non‐responding patients had a median survival of five months. Side effects were minimal, including mild lethargy, rash, fever, and weight gain. This regimen is well tolerated and can be used effectively in metastatic hormone‐receptor‐positive breast cancer.
Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study
Authors: Herson Jay , Sutow Wataru W. , Elder Karin , Vietti Teresa J. , Falletta John M. , Crist William M. , Vats Tribhawan S. , Miale Thomas 
Published: February 2007

AbstractThis report updates experience with the CONPADRI‐I, COMPADRI‐II, and COMPADRI‐III adjuvant chemotherapy programs for the treatment of nonmetastatic osteosarcoma. A total of 200 patients received one of the three regimens. The analysis of response to treatment is based on disease‐free survival time (DFS time). The effect of treatment, age, sex, site of disease involvement, and race on DFS time were investigated. Cox's life‐table regression analysis found only sex to have a significant effect on DFS time with males having 1.8 times the risk of recurrence or death per unit time as female patients (P = 0.004). An analysis of the 81 patients still alive and disease‐free 18 months after the start of treatment shows significantly longer DFS time for CONPADRI‐I than COMPADRI‐II patients (P = 0.01). This trend is true for both male (P = 0.12) and female (P = 0.08) patients.
Acute promyelocytic leukemia in children
Authors: Chan Ka Wah , Steinherz Peter G. , Miller Denis R. 
Published: February 2007

AbstractSixteen children (ages 2–17) with acute promyelocytic leukemia (APL) were studied retrospectively. Diagnosis was based on clinical features and morphological criteria of the FAB classification. Bleeding diathesis was the predominant presenting symptom (>85%), associated with laboratory findings of disseminated intravascular coagulation (DIC). Extramedullary manifestations included skin rash in six patients, gum infiltration in two, and meningeal leukemia in two. Induction therapy consisted of cytosine arabinoside and an anthracycline, with or without other agents. Prophylactic heparinization was given to 12 patients. Six patients (37.5%) failed to achieve remission and died, secondary to hemorrhage in three, and secondary to infection in the remaining three patients. The median duration of remission was 14 months, and the median survival for responders was 21 months. One meningeal leukemia preceded bone marrow relapse despite intermittent intrathecal chemotherapy for prophylaxis. Three patients remain in continuous complete remission 3 years after initial diagnosis.Although childhood APL shares many features of its adult counterpart, the high frequency of extramedullary manifestations and mortality secondary to neutropenia deserves separate attention.
Physical function assessment in patients with advanced cancer
Authors: Wood Carol A. , Anderson Judith , Yates Jerome W. 
Published: February 2007

AbstractAccepted physical therapy assessment techniques were compared with the Karnofsky Performance Status scores in a group of patients with advanced cancer. Assessment of patients' physical functioning by physical therapy evaluation techniques was highly correlated with the Karnofsky Performance Status score. The KPS has been demonstrated to be a reliable assessment tool and is a good indicator of those patients most likely to maintain independent physical function. Extensive physical therapy measures in this patient population appear to offer no advantage over the KPS as an evaluation tool for studies.
Eosinophilic granuloma of the palatal mucosa in a nine‐week‐old infant
Authors: Roper Maryann , Kelly David , Parmley Richard T. , Kheir Sonia M. , Hicks Julius N. 
Published: February 2007

AbstractHistiocytosis commonly presents as a disseminated disease in children under one year of age and is rare in infants less than three months of age. This case describes a nine‐week‐old infant with unifocal eosinophilic granuloma without bone involvement. One year after surgical excision the child is free of disease by roentgenographic and laboratory studies and is growing and developing normally. Thus our patient demonstrates several unique features, which include a young age at presentation without disease dissemination and an unusual site of tissue involvement without bone extension.
Rhabdoid tumor of the kidney: Complete remission induced by cis‐platinum and adriamycin
Authors: Roper Maryann , Parmley Richard T. , Crist William M. , Kelly David R. , Hyland Caryl H. , Salter Merle 
Published: February 2007

AbstractA 4‐month‐old male infant with Stage I rhabdoid tumor of the kidney at presentation subsequently developed pulmonary metastatic disease shortly after diagnosis and initiation of Vincristine and Actinomycin D chemotherapy. The patient was then treated with cis‐platinum and Adriamycin. Within 28 days he achieved a complete remission which was maintained for 5 months. Subsequent recurrent pulmonary lesions failed to regress with radiotherapy and high‐dose cyclophosphamide when used as single sequential agents. Further clinical trials with cis‐platinum and Adriamycin seem warranted since prognosis with this tumor is poor and successful chemotherapy after metastatic dissemination has not been previously reported.
Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas
Authors: Roboz John , Jacobs Allan J. , Holland James F. , Deppe Gunter , Cohen Carmel J. 
Published: February 2007

AbstractIntraperitoneally administered doxorubicin yields high local concentrations that are expected to deliver higher doses to clinically important peritoneal and lymphatic metastatic sites. Two infusions of 20 mg and 30 mg in a patient with residual microscopic intraperitoneal ovarian cancer eradicated her disease. Quantification of serum doxorubicin by HPLC revealed significant levels of the drug and its major metabolite lasting 72 hours. A 50‐mg infusion induced complete remission in endometrial carcinoma; the patient died in 6 months without evidence of abdominal tumor. Complications due to subcutaneous infiltration of doxorubicin and possible systemic effects of sustained high levels of the drug need further investigation to enable the full exploitation of this modality.
Phase I trial of rubidazone (NSC 164011) in children with cancer
Authors: Tan Charlotte T. C. , Mitta Swatantra K. , Steinherz Laurel , Miller Denis R. 
Published: February 2007

AbstractRubidazone was administered to 24 children with advanced solid tumors or leukemia. The dose ranged from 80 to 150 mg/m2/IV daily to a total dose of 160 to 450 mg/m2/course. This course was repeated at intervals of approximately three weeks. Eighteen of 24 patients (75%) had received adriamycin and daunomycin as part of prior chemotherapy. The major toxic effects observed were myelosuppression, nausea, vomiting, mucositis, and skin rash. Four patients developed abnormal echocardiograms following the rubidazone therapy, 2 manifested clinical cardiac failure, of which one had anthracycline cardiomyopathic changes on autopsy. One of 7 adequately treated ALL patients achieved M2 marrow and improved peripheral counts for 3 weeks. One of the 2 neuroblastoma patients had subjective improvement of bone pain for 2 months. Rubidazone, in a previously heavily treated group of patients used in this study, had dosages of 360 and 450 mg/m2 which produced marrow hypoplasia to aplasia, with only minimal responses.
Phase II evaluation of mitomycin C (MMC) in children with refractory solid tumors using the single high‐intermittent‐dose schedule
Authors: Gutierrez Manuel L. , Evans Audrey , Rohrbaugh Thomas , Belasco Jean , Lee Francis H. , Crooke Stanley T. 
Published: February 2007

AbstractNine evaluable patients with refractory solid tumors received mitomycin C as a single intravenous injection at a dose of 20 mg/m2 at 6‐ to 8‐week intervals. Toxicity was tolerable. One patient with Wilms'tumor had a transient decrease in liver size. Pharmacokinetic data on three patients have suggested that the disposition of mitomycin C were comparable to those obtained in adults.
Cardiac changes with cyclophosphamide
Authors: Steinherz Laurel J. , Steinherz Peter G. , Mangiacasale Deborah , O'Reilly Richard , Allen Jeffrey , Sorell Michael , Miller Denis R. 
Published: February 2007

AbstractSerial echocardiographic (ECHO) studies were obtained on 40 pediatric patients (pts) treated with ≥ 80 mg/kg cyclophosphamide (CPM) (range 80–200 mg/kg) in 1 week. Patients were treated for solid tumors and prior to marrow transplant. Echo changes ocurred in 10/13 pts who received CPM ≥ 170 mg/kg over four days, and in 11/19 pts who received 120–140 mg/kg dose over two days and who had previously received ≥ 100 mg/m2 anthracyclines with or without radiation. No changes were seen in eight pts who had 80–160 mg/kg CPM and < 100 mg/m2 anthracyclines. The observed changes occurred approximately 1 week after CPM and persisted for days to weeks. Pericardial effusion seen in 15 pts was successfully treated with furosemide in 13. Two died with hemorrhagic pancarditis. Other changes seen were increased end diastolic left ventricular diameter, decreased fractional shortening and abnormal left ventricular preejection period/ejection time ratios. Thus, cardiac effects of high dose CPM are not rare in children. Patients receiving ≥ 170 mg/kg CPM in 1 week or 120 mg/kg in 1 week after ≥ 100 mg/m2 anthracyclines are at particular risk.
Marrow transplantation for children with acute nonlymphoblastic leukemia in first remission
Authors: Sanders Jean E. , Thomas E. Donnall 
Published: February 2007

AbstractThirteen children between the ages of two and 17 years with acute nonlymphoblastic leukemia in first remission were transplanted from HLA matched sibling donors. They were transplanted at a median of four months [2–8] following diagnosis. The preparative regimen of cyclophosphamide and total body irradiation was well tolerated. Two patients died of pneumonia 66 and 94 days following transplant. One patient relapsed at 431 days, and died of leukemia at 490 days. Ten are living in remission 20–53 months following transplantation. None are on maintenance chemotherapy, and all lead normal lives. As yet, growth is not impaired.
Myocardial injury immediately following adriamycin administration
Authors: Oster Martin W. , Rakowski Thomas J. 
Published: February 2007

AbstractA patient is described who developed chest pain during adriamycin administration given for the first time for small cell carcinoma of the lung. This was associated with the acute onset of atrial fibrillation with a rapid ventricular response. Although no electrocardiographic changes of myocardial ischemia developed, serum isoenzyme studies suggested that myocardial injury had occurred. The patient recovered but died suddenly three weeks later. Physicians should be aware of possible life‐threatening arrhythmias developing during or shortly after adriamycin administration.
Neuroblastoma in a pair of identical twins
Authors: Mancini Antonia F. , Rosito Pasquale , Faldella Giacomo , Serra Luigi , Vallicelli Roberto , Vecchi Vico , Vivarelli Franca , Paolucci Guldo 
Published: February 2007

AbstractHereditary neuroblastoma in a pair of identical twins is reported. In one of the twins the tumor occurred in fetal life and caused death of the twin before birth; in the other one, the tumor occurred at two months of life as IV‐S neuroblastoma in the liver with primary tumor undetected. The unusual clinical course of the latter case is described: twice there was tumor regression, but in spite of treatment, fatal uncontrolled growth occurred. The family history, characterized by neoplasms of dissimilar cell types but without additional cases of neuroblastoma, is also detailed.
Major bone lesions in acute lymphoblastic leukaemia
Authors: Hughes R. G. , Kay H. E. M. 
Published: February 2007

AbstractThe records of 1471 patients with ALL entered into UKALL trials II‐V (1972–1977) were studied, and major bone lesions at diagnosis were recorded in 47 (3.2%). These were found predominantly in young patients (median age 5 years), equally in both sexes, and were seen to be associated with a low blood leucocyte count and prolonged remissions.
Transitional cell carcinoma of the bladder metastatic to the breast
Authors: Berkman Aron W. , Markman Maurie , Murphy Joseph B. , Lenhard Raymond E. 
Published: February 2007

AbstractThis report is the first described case of transitional cell carcinoma of the bladder metastatic to the female breast. The patient is a 42‐year‐old woman who underwent radical cystectomy three months prior to presentation with two asymptomatic right breast masses as the first evidence of widely metastatic bladder carcinoma. The mode of presentation is similar to that seen with other tumors metastatic to the breast and requires the clinician and pathologist to be able to distinguish this diagnosis from primary breast carcinoma.